

20. (Currently Amended) A compound as described in ~~any one of claim 17 to 19~~ claim 17 wherein R₁ is cyano, methyloxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, ethyloxycarbonyl.
21. (Currently Amended) A compound as described in ~~any one of claim 17 to 20~~ claim 17 wherein R₂ is hydrogen or methyl.
22. (Currently Amended) A compound as described in ~~any one of claim 17 to 21~~ claim 17 wherein R₁ is cyano and R₂ is hydrogen or methyl.
23. (Currently Amended) Use of a compound of formula (I) as defined in ~~any one of claims 17 to 22~~ claim 17 for the manufacture of a medicament for preventing, treating or combating infection or disease associated with infection with HIV virus.
24. (Currently Amended) Use of a compound of formula (I) as defined in ~~any one of claims 17 to 22~~ claim 17 for the manufacture of a medicament for inhibiting the replication of HIV virus.
25. (Currently Amended) Use of a compound of formula (I) according to claim 23 ~~or 24~~ characterized in that the reverse transcriptase of the HIV virus is mutant.
26. (Currently Amended) A pharmaceutical composition, comprising an effective amount of at least one compound of formula (I) as defined in ~~any one of claims 1 to 17~~ claim 1 and a pharmaceutically tolerable excipient.
27. (Currently Amended) A product containing at least one compound of formula (I) as defined in ~~any one of claims 1 to 17~~ claim 1 and an antiretroviral agent as a combined preparation for the simultaneous, separate or sequential use in antiretroviral therapy.